Shoppers Drug Mart and TruTrace Technologies Successfully Complete Phase 1 of the Medical Cannabis Verification Pilot Program

采购商药品和卡车技术成功地完成了第一阶段的医用大麻验证试验计划

2019-08-14 22:39:11 CFN Media Group

本文共2703个字,阅读需7分钟

TORONTO, Aug. 14, 2019 /CNW/ – TruTrace Technologies Inc.  , creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, today announced the successful completion of Phase 1 of the blockchain-secured pilot program with Shoppers Drug Mart . The Pilot Program is specifically designed to increase transparency, interoperability and product identification within the medical cannabis industry. Shoppers has also engaged TruTrace and Deloitte Canada LLP   to execute Phase 2 of the Pilot Program, with full production and implementation of TruTrace’s StrainSecure platform targeted for late November 2019. Phase 2 of the Pilot Program, using Deloitte’s project management and advisory capacity and TruTrace’s StrainSecure™ system, will be focused on developing a unified approach to medical cannabis standards, onboarding licenced producers and other partners to track and trace all product history—from genome to distribution.  The program is expected to help researchers and clinicians to match therapeutic outcomes to specific genetic and chemical profiles, and provide physicians, pharmacists, and patients with greater confidence in the products they prescribe or consume. Under their StrainSecure™ system, the TruTrace team collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the technology. “We have been encouraged by the response to this traceability initiative. There is a clear consensus within the cannabis industry that the source and quality of medical cannabis must be transparent and identifiable in order to meet the expectations of patients and health care practitioners,” said Ken Weisbrod, Vice President of Business Development, Shoppers Drug Mart. “It is more important than ever to be able to assure all stakeholders, from regulators to health care practitioners, that the medical cannabis industry is taking the necessary steps to establish the infrastructure required to deliver standardized, consistent medication to our patients.  Shoppers has turned to two trusted leaders, TruTrace and Deloitte Canada LLP, to assist us in the second phase of the project.” “As the cannabis sector continues to rapidly evolve in Canada, the industry needs to increase transparency to all stakeholders by demonstrating adherence to rigorous procedures to maintain the overall integrity of the supply chain,” said David Stewart, Partner within Deloitte’s Forensics practice. “Strengthening traceability and verification of cannabis products will bring benefits to the industry as a whole, and most importantly, build confidence and accountability into the cannabis medical value chain. We are proud to be part of such an important initiative given Deloitte Canada’s leadership in the cannabis space.” First announced in early June at the second annual World Cannabis Congress in Saint John, New Brunswick, the Pilot Program is being developed and implemented by TruTrace utilizing their proprietary StrainSecure™ platform. StrainSecure serves as the central hub for identity management, asset tracking, validation and product authentication, as well as a master registry for standardized testing, product verification, and quality assurance. About TruTrace Technologies: TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace’s technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market. About Shoppers Drug Mart: Shoppers Drug Mart is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart (Pharmaprix in Québec). With almost 1,300 Shoppers Drug Mart and Pharmaprix stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns 47 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy (Pharmaprix Simplement Santé in Québec), and provides cosmetic dermatology services at two standalone locations, the Beauty Clinic. As well, the company owns and operates 43 corporate Wellwise by Shoppers Drug Mart stores and an ecommerce site Wellwise.ca, making it the largest Canadian retailer of home health care products and services. In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, and MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities. Shoppers Drug Mart is an independent operating division of Loblaw Companies Limited. Disclaimer for Forward-Looking Information This news release includes forward-looking information within the meaning of Canadian securities legislation, concerning the business of TruTrace, including statements regarding: the Pilot Program, including its intended scope, characteristics, and perceived benefits; the ability of TruTrace Technologies’ platform to increase transparency, interoperability and product identification within the medical cannabis industry; that the initiative should allow researchers and clinicians to match therapeutic outcomes to specific genetic and chemical profiles, and provide physicians, pharmacists, and patients with greater confidence in the products they prescribe or consume; and that Phase 2 of the Pilot Program is expected to be completed by November 2019, followed by full production and implementation. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct and actual results and future events could differ materially from those anticipated in such information. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with: general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks beyond the Company’s control. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are cautioned not to place undue reliance on any forward-looking information contained in this news release. Forward-looking information contained in this news release is provided as of the date of this news release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. SOURCE TruTrace Technologies Inc. For further information: TruTrace Technologies Inc: Robert Galarza, Chief Executive Officer and Director; Media Relations: Corey Herscu, RNMKR Agency, 416-300-3030; Investor Inquiries: Swapan Kakumanu, Chief Financial Officer, 844-656-3629, [email protected]
TOROTOONTO ,2019年8月14日/ CNW /- TruTrace Technologies Inc .是第一个为大麻行业注册和跟踪知识产权的完全集成的区块链平台的创始人,今天宣布成功完成与 Shoppers Drug Mart 合作的区块链安全试点项目的第1阶段。试点计划的具体目的是提高医疗大麻行业的透明度、互操作性和产品识别。购物者还聘请 TruTrace 和 Deloitte Canada LLP 执行试点计划第2阶段,全面生产和实施 TruTrace 的 StrainSecure 平台,目标是2019年11月下旬。 试点计划第二阶段将利用德勤的项目管理和咨询能力以及 TruTrace 的 StrainSecure ™系统,重点开发一种统一的医用大麻标准方法,对登机牌生产商和其他合作伙伴进行跟踪和追踪所有产品历史——从基因组到分销。该项目预计将帮助研究人员和临床医生将治疗结果与特定的基因和化学特征相匹配,并为医生、药剂师和患者提供对他们开出或消费的产品更有信心。 在 StrainSecure ™系统下, TruTrace 团队收集植物测试数据,并以植物批次进行基因组学验证,然后在支持区块链的数据库中注册,用于知识产权保护和菌株验证。从植物中收集的所有信息,包括它们的分子和化学成分,都可以通过该技术进行跟踪。 “我们对这项可追溯性倡议的反应感到鼓舞。“大麻行业内部有一个明确的共识,即医用大麻的来源和质量必须透明和可识别,以满足患者和医疗保健从业人员的期望,” Shoppers Drug Mart 商业发展副总裁 Ken Weisbrod 说。“比以往任何时候都更重要的是,要能够向所有利益相关者(从监管机构到医疗从业者)保证,医用大麻行业正在采取必要步骤,建立必要的基础设施,为我们的患者提供标准化、一致的药物。购物者已经转向 TruTrace 和 Deloitte Canada LLP 这两个值得信赖的领导者,帮助我们完成项目的第二阶段。” 德勤( Deloitte )法医业务合伙人戴维•斯图尔特( David Stewart )表示:“随着加拿大大麻行业继续快速发展,该行业需要通过证明遵守严格的程序来保持供应链的整体完整性,提高所有利益相关者的透明度。”“加强大麻产品的可追溯性和验证,将给整个行业带来好处,最重要的是,将信心和问责纳入大麻医疗价值链。考虑到德勤加拿大在大麻领域的领导地位,我们很自豪能成为这一重要举措的一部分。” 第一次宣布在6月初在第二届世界大麻大会在圣约翰,新不伦瑞克,试点计划正在开发和实施的 TruTrace 利用他们的专有 StrainSecure ™平台。StrainSecure 是身份管理、资产跟踪、验证和产品认证的中心枢纽,也是标准化测试、产品验证和质量保证的主注册中心。 关于 TruTrace 技术: TruTrace Technologies 公司开发了第一个用于大麻行业知识产权注册和跟踪的集成区块链平台。TruTrace 的技术允许大麻种植者和饲养者识别并保护其知识产权。它还简化了行政程序,降低了对合法大麻进行遗传和强制性质量控制测试的成本。TruTrace 的技术是专有的、不可变的和密码安全的,从而建立了大麻从所有权到市场的准确和永久的帐户。 关于购物药店: 在加拿大零售业中,购物者药品超市是最受认可和信赖的品牌之一。该公司是以 Shoppers Drug Mart (魁北克省的 Pharmaprix )名义经营的全服务零售药店的许可人。该公司拥有近1300家 Shoppers Drug Mart 和 Pharmaprix 商店,在每个省和两个地区的主要经营地点,是加拿大最方便的零售商之一。该公司还许可或拥有47家以 Shoppers Simpley Pharmacy Pharmaprix Simplement Sant é名义经营的医疗诊所药店,并在 Beauty Clinic 两个独立地点提供美容皮肤科服务。此外,该公司还拥有和经营43家 Wellwise 公司由 Shoppers Drug Mart 商店和电子商务网站 Wellwise 。成为加拿大最大的家庭保健产品和服务零售商。除零售门店网络外,公司拥有 Shoppers Drug Mart Specialty Health Network Inc .,专业药品配送、药店及综合患者支持服务的提供商,以及向长期护理设施提供药品产品和服务的 MediSystem Inc 。沃尔玛是 Loblaw 公司的一个独立运营部门。 有关前瞻性资料的免责声明 本新闻稿包括加拿大证券立法意义内的前瞻性信息,涉及 TruTrace 的业务,包括以下声明:试点计划,包括其预期范围、特点和预期效益; TruTrace Technologies 平台提高透明度的能力;医用大麻行业内的互操作性和产品识别;该举措应使研究人员和临床医生能够将治疗结果与特定的遗传和化学概况相匹配,并使医生、药剂师和患者对其处方或消费的产品有更大的信心;试点方案第二阶段预计在2019年11月前完成,随后全面生产和实施。尽管本公司认为该等前瞻性资料所依据的预期及假设是合理的,不应过分依赖前瞻性信息,因为本公司无法保证其将被证明是正确的,且实际结果和未来事件可能与此类信息中预期的结果存在重大差异。前瞻性信息必然涉及已知和未知的风险,包括但不限于与以下相关的风险:一般经济条件;不利的行业事件;市场损失;加拿大、美国未来的立法和监管发展;和其他方面;无法从内部和外部来源获得足够的资本,和/或无法以优惠条件获得足够的资本;以及公司无法控制的其他风险。由于许多已知和未知的风险、不确定性和其他因素,其中许多因素无法控制,事件或情况可能导致实际结果与预测结果存在重大差异。读者应注意不要过度依赖本新闻稿中的任何前瞻性信息。本新闻稿中包含的前瞻性信息截至本新闻稿发布之日提供。除适用的证券法律要求外,本公司不承担因新信息、未来事件或结果或其他原因而公开更新任何前瞻性信息的任何意图或义务。 SOURCE TruTrace Technologies Inc . 更多信息: TruTrace Technologies Inc :首席执行官兼董事 Robert Galarza ;媒体关系: Corey Herscu , RNMKR Agency ,416-300-3030;投资者问询: Swasan Kakumanu ,首席财务官,844-656-3629,[电子邮件受保护]

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文